Australian Clinical Labs (ASX:ACL) has announced that Crescent Capital has sold its 30.12% shareholding in a block trade, resulting in Crescent Capital no longer holding shares in ACL via its various investment vehicles. ACL has no further information at this time.
We confirm that Crescent Capital has divested its shareholding in ACL. We appreciate their past support and look forward to continuing our mission of providing high-quality pathology services to our clients and contributing to the improvement of patients' lives.
Australian Clinical Labs (ASX:ACL) has announced the sale of Crescent Capital's 30.12% shareholding in a block trade. The company has no further information at this time. Looking ahead, ACL remains committed to its mission of combining talented people, medical and scientific leadership, and innovative technologies to empower decision making that saves and improves patients' lives.